March 25, 2017

March 10, 2017, 9:02 am
No comments

Tags:

Aaron Traywick, CEO, Ascendance Biomedical

Thumbnail for Aaron Traywick, CEO, Ascendance Biomedical

 

Aaron Traywick
traywickaaron@gmail.com
http://www.ascendancebiomed.com

About Ascendance Biomedical
Ascendance Biomedical is a team of physicians, scientists and entrepreneurs unified in the mission to save and improve lives.

The company provides products and services which enable customers to access the most cutting-edge biomedical technologies and treatments in the world.

AB provides medical care and treatment, assistance with flights, accommodation, travel instructions, the processing of medical records, direct connection with medical personnel upon arrival, analysis of your case to get you the best price with local physicians and – most importantly – set you up to receive the required treatments and interventions for your condition.

About Aaron Traywick
Aaron Traywick serves as the CEO of Ascendance Biomedical (AB) and the managing director of AB’s offshore clinical trials offerings. Aaron is a community organizer, public policy professional and human rights advocate. He has served in various public policy leadership and service capacities in positions ranging from local and state government to members of the United States Congress.

Medical Travel Today (MTT): Can you give our readers some background information about your company?

Aaron Traywick (AT): Our company works to increase access for patients in a variety of terminal and treatment conditions that can’t be met here in the U.S. or in a reasonable timeframe for their needs.
We have a network of clinics, as well as research clinics in other countries to include patients for their enrollment and participation in experimental trials in which they can participate in the treatment and also help to generate scientific data necessary to advance the breakthrough of treatments here in the U.S.

MTT: How would you say this model supports the emergence of breakthrough treatments and technologies in healthcare?

AT: One primary example is the model we are currently using with our Inovium brand – our Inovium Ovarian Rejuvenation Trial.

We have partnered with researchers in Greece, San Diego, and the University of California-Berkeley, and we have pioneered the first PRP-based treatment for the reversal of menopause, one of the only known treatments for the reversal of menopause, and the restoration of healthy fertility levels in women.

For this model, we have designed rigorous scientific protocols following FDA best practices, and work to have clients within the fertility space refer them over to our clinics in Greece and San Diego.

Additionally, we have worked with the scientific community to have pre- and post-treatment, bloodwork and analysis done so that we can actually see the overall effect in women’s health as a result of these trials.

This model is used with other companies that we work with in breakthrough treatments particularly in the field of mitigation of aging related disease for life extension.

We partner with many companies who have developed treatments and have experimental treatments on deck to address the underlying conditions that lead to terminal illnesses of aging.

MTT: You mentioned Greece but what other regions does your model serve?

AT: We serve globally and maintain relationships with three clinics around the world that are providing the Cimavax lung cancer vaccine currently available only in Cuba.

MTT: What fees are associated with this type of service?

AT: We have a very basic percentage that we request the patient provides if they can actually move forward with treatment.
Ascendance never asks anything of these patients if they are terminal, which many of them are. We work with those who can’t afford the treatments once we process their medical records and receive approval, as well as our other clinics and non-profit agencies, to ensure that they can get some form of treatment for their condition.

When it comes to the clinical trials, each model requires different costs for delivery of the treatment according to our clinics. We also provide support for the patient and their insurance coverage to cover the cost of pre- and post-bloodwork and bloodwork analysis through our partner agencies.

About an 80 percent reinvestment of all our revenue goes directly into research and development for new treatment options and the provision of new facilities for delivery.

MTT: What is the latest research that you’ve conducted?

AT: The latest and most fascinating research thus far has been in the first senolytics treatment.

Senolytics can be regarded as the next generation of drugs like metformin, or rapamycin – which we’ve heard a lot about for being effective interventions for not just Type 2 diabetes and high blood pressure but for a variety of different aging related conditions – like multiple cancers, cognitive diseases, dementia, cardio-vascular diseases and heart diseases.

These drugs appear to be effective in the underlying causes and processes that lead to aging even in youth.

Senolytics take it one step further by reducing the overall senescent cells in the body, which are essentially junk cells that are highly associated with the proliferation of cancer and other age related conditions in the body.

Mayo Clinic did some research and discovered that the combination was able to decrease the senescent cell count by about 40 percent, as well as increase muscular endurance significantly with just one five-day treatment that lasted in terms of a positive effect up until six months later.

This was pretty landmark because most pharmaceutical treatments do not last that long typically after just one simple five-day use.

Our research was able to conduct those trials and confirm both the safety and the endurance in the short term, as well as increase the testosterone levels in the male subjects. The research is ongoing and fascinating.

It is even more fascinating to know that there really is this potential in humans as well.

MTT: How do you think preventative care can be more accessible in medical tourism?

AT: Preventative care hasn’t been given a lot of support particularly in terms of federal funding in the U.S. and is the least funded out of all the practiced medicine that we know of.

There is significant demand for performance – an increase in maximizing performance in athletes and body builders, Silicon Valley types or what have you.

For us, this represents the same principle; it is prevention and it is also showing that you’re not just preventing diseases, disease proliferation and aging by engaging medical tourism. You’re also maximizing your performance, competitiveness and your fitness right here, right now.

By engaging medical tourism in this way, you are really investing in your future, as well as in the here and now and in what level of help would be required for you to continue to maintain peak performance.

MTT: What changes do you expect to see in the future of the medical tourism industry?

AT: If the Affordable Care Act is repealed, then I think we can continue to see many new competitive markets and competitive countries develop, providing much lower air travel, lodging and facilities to folks of all income classes here in the U.S. We will be able to take advantage of that, and medical tourism will grow exponentially. It is only a matter of time before the Chinese government plans execution to mass market medical tourism around the world in the same way that they have taken on the mass marketing of various treatments that have yet to be developed at affordable levels for citizens of all income.

Share this:

del.icio.us DiGG Google StumbleUpon Google Buzz Microsoft Live MiXX RSS PDF

Comments are closed.

Comments are closed.